Name: Surgery and HIPEC in relapse for all patients with ovarian cancer? by ESMO Podcasts
Duration: 15 min 26 s
Description: Dr Shira Peleg Hasson, from The Royal Marsden NHS Foundation Trust, London, UK, leads a debate between Dr Philipp Harther (Kliniken Essen-Mitte, Essen, Germany) and Dr Christian Marth (Innsbruck Medical University, Austria) on he use of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer treatment.

Professor Johan Vansteenkiste, an associate Editor of Annals of Oncology, discusses the recent publication of Felip et al. that reports a study of the intracranial, and extracranial efficacy of lorlatinib, a potent, brain-penetrant, third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI)in ALK-positive NSCLC that progressed on second-generation ALK TKIs.
Felip E et al. Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. Ann Oncol 2021; 32: https://doi.org/10.1016/j.annonc.2021.02.012
Stinchcombe TE. Lorlatinib in the treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.  Ann Oncol 2021; 32: https://doi.org/10.1016/j.annonc.2021.03.002

Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive NSCLC

Dr Shira Peleg Hasson, from The Royal Marsden NHS Foundation Trust, London, UK, leads a debate between Dr Philipp Harther (Kliniken Essen-Mitte, Essen, Germany) and Dr Christian Marth (Innsbruck Medical University, Austria) on he use of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer treatment.

Surgery and HIPEC in relapse for all patients with ovarian cancer?

Professor Florian Lordick discusses his recent editorial in Annals of Oncology that considered the results of theARTIST 2 and CRITICS trials in gastric cancer, both published in the March issue of the journal.
Adjuvant radiotherapy for gastric cancer—end of the road? F. Lordick, M. Nilsson & T. Leong https://doi.org/10.1016/j.annonc.2020.12.006
ORIGINAL ARTICLEAdjuvant chemotherapy is superior to chemoradiation after D2 surgery forgastric cancer in the per-protocol analysis of the randomized CRITICS trial. W. O. de Steur, R. M. van Amelsfoort, H. H. Hartgrink et al. https://doi.org/10.1016/j.annonc.2020.11.004
A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial. S. H. Park, D.H.Lim, T. S. Sohn et al. https://doi.org/10.1016/j.annonc.2020.11.017

Adjuvant radiotherapy for gastric cancer?

OncologyPRO: The home of ESMO’s educational and scientific resources. Representing more than 35,000 oncology professionals from 172 countries worldwide, ESMO is a reference for oncology education and information. Driven by a shared determination to secure the best possible outcomes for patients, ESMO is committed to standing by those who care about cancer through addressing the diverse needs of #ONEoncologycommunity, offering #educationforLIFE, and advocating for #accessiblecancerCARE.

Surgery and HIPEC in relapse for all patients with ovarian cancer?

ESMO Podcasts

Related tracks